Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.04 USD
-0.03 (-1.44%)
Updated Jul 24, 2024 03:56 PM ET
After-Market: $2.04 0.00 (0.00%) 6:46 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Cellectis S.A. (CLLS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.80 | $10.00 | $3.00 | 228.50% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Cellectis S.A. comes to $6.80. The forecasts range from a low of $3.00 to a high of $10.00. The average price target represents an increase of 228.5% from the last closing price of $2.07.
Analyst Price Targets (5 )
Broker Rating
Cellectis S.A. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CLLS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.29 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/31/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
4/30/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
11/29/2023 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
11/7/2023 | Wells Fargo Securities | Yanan Zhu | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $6.80 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | -0.33 |